Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AbbVie’s Veliparib Missed Goals in Two Late-Stage Studies

By Ryan Bushey | April 20, 2017

AbbVie announced on Wednesday its experimental cancer drug missed primary endpoints in two different phase 3 studies.

The drug is called veliparib, which is an investigational PARP inhibitor being evaluated in multiple tumor types.

Investigators running these trials were testing velaparib’s impact in conjunction with a chemotherapy regimen on patients with non-small cell lung cancer (NSCLC) and early-stage triple-negative breast cancer (TNBC).

Results from the NSCLC study indicated the drug failed to improve the overall survival of these patients who smoked within the past 12 months and had more than 100 smoking events in their lifetime, according to Reuters.

Also, the drug was unable to achieve its main goal of complete pathologic response in the TNBC study with 312 patients.

“Research shows there is a role for PARP inhibitors in cancers associated with DNA repair deficits, such as those with BRCA mutations. In these clinical trials, we wanted to explore whether a PARP inhibitor could augment chemotherapy in patients with squamous non-small cell lung cancer and triple negative breast cancer by disrupting the repair of cancer cells,” said AbbVie’s Vice President of Oncology Clinical Development Gary Gordon, M.D., Ph.D., in a statement.  

“Unfortunately, these data do not support the use of veliparib in combination with chemotherapy in these patients,” continued Gordon.

Detailed results of these studies will either be published in a peer-reviewed journal or at an upcoming medical meeting.

AbbVie has been attempting to bring new drugs to market that could offset potential losses from increased biosimilar competition against its lucrative Humira franchise, wrote FierceBiotech.

The company is expected to present lung cancer data for Rova-T, a drug AbbVie acquired in a billion dollar acquisition on a small startup called StemCentrx, later this year along with a potential separate presentation on its experimental JAK1 inhibitor ABT-934.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE